Turkish Journal of Nephrology
Original Article

MYCOPHENOLATE MOFETİL TREATMENT IN PRIMARY GLOMERULONEPHRITIS THAT IS RESISTANT TO TREATMENT (RETROSPECTIVE ANALYSIS)

1.

İstanbul Tıp Fakültesi Nefroloji Bilim Dalı, İSTANBUL

2.

İstanbul Tıp Fakültesi İç Hastalıkları Anabilim Dalı, İSTANBUL

3.

SSK Samatya Hastanesi Nefroloji Bölümü, İSTANBUL

4.

SSK Göztepe Hastanesi Nefroloji Bölümü, İSTANBUL

Turkish J Nephrol 2002; 11: 93-98
Read: 633 Downloads: 476 Published: 14 March 2019

The success rate of different treatment protocols for primary glomerulonephritis (PGN) is 60-70%. Recently, it has been suggested that in somel patients who are unresponsive to standard treatments, \ mycophenolate mofetil (MMF)- the pro-drug of mycophenolic acid- can be used. In our study, the \ results of 20 patients suffering from PGN (7 membranous nephropathy, 6 membranoproliferative GN, 3 focal segmentary glomerulosclerosis, 2 Ig A nephropathy, 1 proliferative GN and 1 mesangioproliferative GN) are investigated. The patients that were given MMF for 2-13 months (mean 7.35 months) were followed up for 8.95 month on the j average and given MMF l-2g/day. In the patients that \ had proliferative lesion (membranoproliferative GN, \ Ig A nephropathy, proliferative and\ mesangioproliferative GN) in histopathological"\ examination the complete response rate was found\ 70% whereas in the patients that did not have proliferative lesion, it was found 30%. Apart from this, in 3 patients the steroid sparing effect of MMF was observed while no serious side effect was noted.

In conclusion, MMF is a well tolerable new \ immunosuppressive drug that enables steroid dose: reduction and can be effective in the treatment of PGNs in which proliferative lesion is prominent. The \ prospective, controlled and large studies about this subject would be exciting. 

Files
EISSN 2667-4440